Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
September 19 2022 - 4:05PM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced the appointment of Lauren Silvernail to its Board of
Directors and as the Chairperson of its Audit Committee.
“We welcome Lauren to our Board of Directors. Her strategic,
operational and financial experience in the life sciences industry
will be a strong addition,” said Julie Eastland, President and
Chief Executive Officer of Harpoon Therapeutics. “We look
forward to Lauren’s guidance as we continue to execute our business
plan and advance our novel class of T cell engagers in clinical
trials.”
Lauren Silvernail has three decades of experience in lead
financial and business development roles. She has led and played
key roles in a broad range of transactions, including mergers,
acquisitions, and financings. She most recently served as Chief
Financial Officer and Executive Vice President of Corporate
Development of Evolus, Inc., an aesthetic medicine company, where
she led fundraising activities and helped establish the
infrastructure for the U.S. commercial launch of the company’s
first approved product. Previously, she served as Chief Financial
Officer and Chief Business Officer at Revance Therapeutics, Inc.
and held corporate development roles at ISTA Pharmaceuticals Inc.,
Allergan and other companies. Lauren is currently a member of the
Board of Directors of Nicox S.A., an international ophthalmology
company. She earned an M.B.A. in finance and accounting from the
Anderson Graduate School of Management at UCLA, and a B.A. in
biophysics from the University of California, Berkeley.
“My experience has shown me that both strong science and
passionate people are necessary for a company to accomplish its
mission, and I believe Harpoon’s proprietary platforms and
dedicated workforce represent a company on the path to success,”
said Lauren Silvernail. “I am pleased to partner with Julie and my
fellow Board members as we continue to progress Harpoon’s pipeline
of T cell engagers.”
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy
company developing a novel class of T cell engagers that harness
the power of the body’s immune system to treat patients suffering
from cancer and other diseases. T cell engagers are engineered
proteins that direct a patient’s own T cells to kill target cells
that express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as ”believe,” “look forward,” “plan,” “target,”
“will,”, and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include, but are not limited to, statements
about the development and advancement of Harpoon Therapeutics’
platforms and product candidates, Harpoon Therapeutics’ business
prospects, and expectations regarding strengthening of Harpoon’s
leadership team and other statements that are not historical fact.
Many factors may cause differences between current expectations and
actual results, including unexpected safety or efficacy data
observed during clinical studies, preliminary data and trends may
not be predictive of future data or results, may not
demonstrate safety or efficacy or lead to regulatory approval by
the FDA or other regulatory agencies, clinical trial site
activation or enrollment rates that are lower than expected,
unanticipated or greater than anticipated impacts or delays due to
COVID-19, changes in expected or existing competition, changes in
the regulatory environment, the uncertainties and timing of the
regulatory approval process, the timing and results of unexpected
litigation or other disputes, and the sufficiency of Harpoon
Therapeutics’ cash resources. These and other factors that may
cause Harpoon Therapeutics’ actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Harpoon Therapeutics’ filings with
the U.S. Securities and Exchange Commission, including under
“Risk Factors” in Harpoon Therapeutics’ quarterly report on Form
10-Q for the quarter ended June 30, 2022 and future filings
by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Contacts:
Investors:ICR WestwickeRobert H. UhlManaging
Director858-356-5932 robert.uhl@westwicke.com
Media:uncapped communications862-368-4464media@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Sep 2023 to Sep 2024